Improving R&D Efficiency through Open Innovation
First written in FY2019. 3 of 4 entries say "Restated". Latest entry: FY2024-Q3.
16 other companies' latest entry also says "Restated".
- FY2024-Q3RestatedAnnual report
「We will apply and expand our core technologies in glycoscience to create new development projects in existing areas and innovative research projects, including new disease areas, while promoting various alliances. Through these efforts, we aim to achieve the early and continuous launch of new drugs that will be key to future business growth.」
The company continues its policy of creating new-drug development themes and bringing products to market sooner and on an ongoing basis through the application of core technologies and various alliances. - FY2020-Q3RestatedAnnual report
「In addition to our own technologies, we will actively incorporate highly compatible technologies held by other companies, seek to maximize synergies, expand the number of new-drug development projects and accelerate their progress.」
The company continues its open innovation policy of incorporating technologies from other companies to maximize synergies, expand new-drug development projects and accelerate their progress. - FY2020-Q2RestatedAnnual report
「In addition to our own technologies, we will actively incorporate highly compatible technologies held by other companies, seek to maximize synergies, expand the number of new-drug development projects and accelerate their progress.」
The company reaffirmed its open innovation policy of incorporating technologies from other companies to maximize synergies, expand new-drug development projects and accelerate their progress. - FY2019First statedAnnual report
「We will promote an open innovation strategy to improve the efficiency of research and development.」
Separately from expanding domestic and overseas carbohydrate research networks, the company identified for the first time its open innovation strategy as a means of improving R&D efficiency.